Renoprotective effect of edaravone in acute limb ischemia/reperfusion injury

Background: In this experimental study, we aimed to investigate the efficacy of edaravone on renal injury due to acute lower limb ischemia/reperfusion in a rat model. Methods: Between June 2015 and August 2015, a total of 40 male Wistar rats were used in this study. The rats were randomly divided into the sham, ischemia/reperfusion, edaravone, and solvent groups (n=10 in each). The infrarenal abdominal aorta was clamped for 120 min and was, then, reperfused for 120 min after clamp removal. Edaravone was administered intravenously 30 min before the induction of ischemia. Serum and kidney tissue samples were subjected to biochemical and histopathological analyses. Results: Edaravone decreased the serum and tissue malondialdehyde levels in the ischemia/reperfusion group. The serum superoxide dismutase activity in the edaravone group was significantly higher than the ischemia/reperfusion and solvent groups. The serum nitric oxide level in the ischemia/reperfusion group was numerically higher than the sham group. The serum nitric oxide level was decreased by edaravone. The serum nitric oxide level was lower in the edaravone group than the solvent group. The tissue nitric oxide level was significantly higher in the ischemia/reperfusion than the sham group. In the ischemia/ reperfusion group, the histopathological changes were improved by edaravone. Conclusion: Edaravone ameliorated renal injury caused by lower-limb ischemia/reperfusion. Therefore, it can be used to ameliorate acute ischemia/reperfusion injury during aortic and peripheral vascular surgery.